Peptide-Based Targeted Covalent Inhibitors

Area of Science:

• Medicinal Chemistry
• Drug Delivery
• Nanotechnology

Background:

• Covalent inhibitors are advanced therapeutics with improved selectivity and efficacy in overcoming drug resistance.
• Peptide moieties are increasingly used as ligands in covalent inhibitors due to their binding affinity and biocompatibility.
• Challenges in clinical translation include poor membrane permeability and in vivo stability of peptide-based covalent inhibitors.

Purpose of the Study:

• To review recent advancements in covalent inhibitors featuring peptide ligands or delivered via peptide assemblies.
• To explore the design strategies, mechanisms, and applications of peptide-based covalent inhibitors.
• To discuss the role of supramolecular assemblies in enhancing covalent inhibitor delivery and efficacy.

Main Methods:

• Systematic review of literature on peptide-based covalent inhibitors and their delivery systems.
• Analysis of structure-activity relationships and design strategies for targeted covalent inhibition.
• Evaluation of self-assembled peptide nanostructures as platforms for drug delivery.

Main Results:

• Peptide ligands enhance targeting and selectivity of covalent inhibitors.
• Self-assembled peptide nanostructures show promise for controlled release and improved in vivo stability.
• Controllable electrophilic warheads are crucial for mitigating off-target effects.

Conclusions:

• Peptide-based covalent inhibitors and their delivery systems represent a promising frontier in drug development.
• Overcoming current limitations through advanced delivery strategies is key for clinical translation.
• Future research should focus on optimizing stability, permeability, and targeted release for next-generation covalent drugs.